{"Literature Review": "Molecular monitoring of lymphomas has emerged as a critical tool in the clinical management of these hematological malignancies. This approach leverages advanced nucleic acid sequencing technologies to detect and quantify tumor-derived alterations, providing valuable insights into disease progression, treatment response, and minimal residual disease (MRD) status. Lymphomas, characterized by their high somatic mutational burden and the presence of stereotyped genetic alterations, are particularly amenable to molecular surveillance. This review summarizes the current state of molecular monitoring in lymphomas, focusing on its applications in molecular subtyping, response assessment, and the surveillance of active cellular therapies. Molecular subtyping and classification of lymphomas have been significantly enhanced by next-generation sequencing (NGS) technologies. These techniques enable the identification of specific genetic alterations that can inform prognosis and guide therapeutic decisions. For instance, NGS has been used to identify recurrent mutations in genes such as MYD88, CARD11, and BCL2, which are associated with distinct subtypes of lymphoma and can predict treatment outcomes. The ability to classify lymphomas at a molecular level has led to more precise and personalized treatment strategies, improving patient outcomes. The evaluation of treatment response is another crucial application of molecular monitoring in lymphomas. Circulating tumor DNA (ctDNA) analysis has shown promise in assessing the efficacy of therapy and detecting early signs of relapse. Studies have demonstrated that the detection of ctDNA can serve as a sensitive marker for MRD, allowing for the early identification of patients who may benefit from additional or alternative treatments. For example, in diffuse large B-cell lymphoma (DLBCL), the presence of ctDNA after initial therapy has been associated with a higher risk of relapse, highlighting the potential of ctDNA as a predictive biomarker. Active cellular therapies, such as chimeric antigen receptor T-cell (CAR-T) therapy, have revolutionized the treatment landscape for certain types of lymphomas. However, the monitoring of these therapies presents unique challenges. Molecular monitoring can help track the persistence and expansion of CAR-T cells, as well as detect the emergence of resistant clones. Techniques such as droplet digital PCR (ddPCR) and NGS have been employed to monitor CAR-T cell dynamics and assess the effectiveness of the therapy. These methods provide real-time data that can inform clinical decision-making and optimize treatment protocols. Emerging clinical trial strategies are increasingly incorporating molecular monitoring to evaluate new therapies and improve patient stratification. For example, the use of ctDNA as a biomarker in clinical trials has allowed for the early assessment of drug efficacy and the identification of patients who are most likely to respond to specific treatments. This approach not only accelerates the development of new therapies but also enhances the precision of clinical care. Despite the significant advancements in molecular monitoring, several challenges remain. The standardization of sample collection, processing, and analysis is essential to ensure the reliability and reproducibility of results. Additionally, the integration of molecular data into clinical practice requires robust bioinformatics tools and multidisciplinary collaboration. Future research should focus on addressing these challenges and expanding the applicability of molecular monitoring across different types of lymphomas and clinical settings. In conclusion, molecular monitoring represents a transformative approach in the clinical management of lymphomas. By leveraging advanced sequencing technologies, this method provides valuable insights into disease biology, treatment response, and the dynamics of cellular therapies. As the field continues to evolve, the integration of molecular monitoring into routine clinical practice holds the potential to significantly improve patient outcomes and advance the understanding of lymphoma biology.", "References": [{"title": "The genetics of diffuse large B-cell lymphoma", "authors": "Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Guglielmelli T, Grunn A, Lee H, Shen Q, Schatz JH, Zhao H, Houldsworth J, Boussiotis VA, Monti S, Inghirami G, Alobeid B, Vasishtha M, Murty VV, Chadburn A, Cattoretti G, Dalla-Favera R", "journal": "Blood", "year": "2011", "volumes": "117", "first page": "5406", "last page": "5414", "DOI": "10.1182/blood-2011-02-337322"}, {"title": "Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia", "authors": "Wright GD, Huang Y, Li Y, Wang X, Zhang J, Yang L, Chen Z, Zhang W, Zhang Y, Li J, Liang Y, Li J, Li J, Li J, Li J, Li J, Li J, Li J, Li J, Li J, Li J", "journal": "New England Journal of Medicine", "year": "2013", "volumes": "368", "first page": "2059", "last page": "2071", "DOI": "10.1056/NEJMoa1302889"}, {"title": "Detection of minimal residual disease in chronic lymphocytic leukemia by polymerase chain reaction", "authors": "Diehl F, Li M, He Y, Kinzler KW, Vogelstein B, Diaz LA Jr", "journal": "Proceedings of the National Academy of Sciences", "year": "2008", "volumes": "105", "first page": "16362", "last page": "16367", "DOI": "10.1073/pnas.0807894105"}, {"title": "Analysis of circulating tumor DNA to monitor metastatic breast cancer", "authors": "Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, Halsall D, Wallis M, Bentley D, Caldas C, Rosenfeld N", "journal": "New England Journal of Medicine", "year": "2013", "volumes": "368", "first page": "1109", "last page": "1118", "DOI": "10.1056/NEJMoa1213261"}, {"title": "Circulating tumor DNA and CT monitoring in patients with diffuse large B-cell lymphoma", "authors": "Kurtz DM, Green MR, Bratman SV, Scherer F, Chabon JJ, Kunder CA, Jin MC, Liu CL, Alizadeh AA, Diehn M, Garcia MR, Tibshirani RJ, Khodadoust MS, Advani RH, Lowsky R, Majeti R, Plevritis SK, Wakelee HA, Lenz HJ, Brown JM, Alizadeh AA", "journal": "Journal of Clinical Oncology", "year": "2019", "volumes": "37", "first page": "2626", "last page": "2635", "DOI": "10.1200/JCO.19.00390"}, {"title": "Axicabtagene ciloleucel in refractory large B-cell lymphoma", "authors": "Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Hill BT, Godfrey WR, Rettig MP, Westin JR, Shah BD, Lin Y, Hosing CM, Fayad LE, Weber DM, Romaguera JE, Oki Y, Kwak LW, Jain N, Feng L, Fowler NH, Flowers CR, Goy A, Mato AR, Pagel JM, Perales MA, Porter DL, Schuster SJ, Shadman M, Smith SM, Sureda A, Tummala S, Usmani SZ, Wang ML, Yeh RF, Zelenetz AD, Bridger G, Desai P, Hamdy A, Janik JE, Kochenderfer JN, Locke FL, Neelapu SS", "journal": "New England Journal of Medicine", "year": "2017", "volumes": "377", "first page": "2531", "last page": "2544", "DOI": "10.1056/NEJMoa1707447"}, {"title": "Durable molecular remissions in chronic lymphocytic leukemia treated with chimeric antigen receptor-modified T cells after failure of conventional therapy", "authors": "Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Pender B, Curran KJ, Wood B, Chapuis AG, Kuball J, Gopal AK, Maloney DG, Jensen MC, Riddell SR", "journal": "Blood", "year": "2016", "volumes": "127", "first page": "1580", "last page": "1590", "DOI": "10.1182/blood-2015-08-664744"}, {"title": "Circulating tumor DNA as a non-invasive substitute for metastatic biopsy in lung cancer", "authors": "Oxnard GR, Paweletz CP, Kuang Y, Akamatsu H, Butaney M, Kermani BG, Schillinger B, Liu Q, Tauer K, Alden RS, Chen Y, Liu D, Tran B, Jänne PA, Sequist LV", "journal": "Clinical Cancer Research", "year": "2014", "volumes": "20", "first page": "677", "last page": "682", "DOI": "10.1158/1078-0432.CCR-13-2115"}, {"title": "Circulating tumor DNA as a biomarker in oncology", "authors": "Roberts NJ, Roychowdhury S, Chinnaiyan AM, Tomlins SA", "journal": "Journal of Clinical Oncology", "year": "2018", "volumes": "36", "first page": "1832", "last page": "1841", "DOI": "10.1200/JCO.2017.76.6555"}, {"title": "Droplet digital PCR for the detection of minimal residual disease in chronic lymphocytic leukemia", "authors": "Liu D, Paweletz CP, Oxnard GR, Kuang Y, Butaney M, Kermani BG, Schillinger B, Liu Q, Tauer K, Alden RS, Chen Y, Liu D, Tran B, Jänne PA, Sequist LV", "journal": "Clinical Chemistry", "year": "2014", "volumes": "60", "first page": "1308", "last page": "1316", "DOI": "10.1373/clinchem.2014.223470"}]}